Update on restructure and cost savings
14 August 2023
Fusion Antibodies plc (AIM: FAB), a contract research organisation
(“CRO”) providing discovery, design, and optimisation services
for therapeutic antibodies to the global healthcare market, announces an
update on the Company’s cost savings and restructuring plans, details of
which were announced on 19 May 2023, at the time of the recent placing
to raise approximately £1.67 million (the “Placing”).
The Company has undertaken and completed a restructuring process set out
at the time of the Placing to reduce annualised costs by approximately
£2.2 million and is on track to realise all the intended savings
outlined. The Company continues to expend cash in a planned manner to
grow the trading aspects of the business including the development of
new services stemming from research and development projects.
As part of the cash saving measures, it is intended that certain
directors of the Company will be issued new ordinary shares in Fusion in
settlement of a portion of their salary. Further announcements
will be made in due course, following the publication of the Company’s
annual report and accounts for the year ended 31 March 2023.
Dr Adrian Kinkaid, CEO of Fusion, commented: “The recent
restructuring, whilst difficult for all those involved, was required
to ensure the business had the financial resources required to reach
profitability. This is now the case, and we continue to focus on
delivering the plan.”
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Adrian Kinkaid, Chief Executive Officer |
Via Walbrook PR | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| James Reeve / Vivek Bhardwaj (Corporate
Finance) Tony Quirke (Sales and Corporate Broking) |
||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the discovery and
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
design, generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation using
Fusion's proprietary CDRx TM platform and the
production of antibody generating stable cell lines to provide material
for use in clinical trials. Since 2012, the Company has
successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects and has an
international, blue-chip client base, which has included eight of the
top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global healthcare industry.
Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new
platforms that will enable Pharma and Biotech companies get to the
clinic faster, with the optimal drug candidate and ultimately speed up
the drug development process.
The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.
